Non-inferiority of dose reduction versus standard dosing of TNF-inhibitors in axial spondyloarthritis
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1478-6362
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Non-inferiority of dose reduction versus standard dosing of TNF-inhibitors in axial spondyloarthritis ; volume:21 ; number:1 ; day:8 ; month:1 ; year:2019 ; pages:1-10 ; date:12.2019
Arthritis Research & Therapy ; 21, Heft 1 (8.1.2019), 1-10, 12.2019
- Urheber
-
Gratacós, Jordi
Pontes, Caridad
Juanola, Xavier
Sanz, Jesús
Torres, Ferran
Avendaño, Cristina
Vallano, Antoni
Calvo, Gonzalo
Miguel, Eugenio de
Sanmartí, Raimon
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s13075-018-1772-z
- URN
-
urn:nbn:de:101:1-2019021122051115108933
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:54 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Gratacós, Jordi
- Pontes, Caridad
- Juanola, Xavier
- Sanz, Jesús
- Torres, Ferran
- Avendaño, Cristina
- Vallano, Antoni
- Calvo, Gonzalo
- Miguel, Eugenio de
- Sanmartí, Raimon
- SpringerLink (Online service)
Ähnliche Objekte (12)
Dose reduction and withdrawal strategy for TNF-inhibitors in psoriatic arthritis and axial spondyloarthritis: design of a pragmatic open-label, randomised, non-inferiority trial
Through the looking glass: understanding non-inferiority
Work Disability in Axial Spondyloarthritis
Handling an uncertain control group event risk in non-inferiority trials: non-inferiority frontiers and the power-stabilising transformation
Non-efficacy benefits and non-inferiority margins: a scoping review of contemporary high-impact non-inferiority trials in clinical cardiology
P190: Cardiovascular Disease in Axial Spondyloarthritis
Targeting inflammatory pathways in axial spondyloarthritis
Novel Therapeutic Targets in Axial Spondyloarthritis
Bayes factors for superiority, non-inferiority, and equivalence designs
Understanding the null hypothesis (H0) in non-inferiority trials
Demonstrating equivalence and non-inferiority of medical education concepts
Nonradiographic axial spondyloarthritis: clinical and therapeutic relevance
Dose reduction and withdrawal strategy for TNF-inhibitors in psoriatic arthritis and axial spondyloarthritis: design of a pragmatic open-label, randomised, non-inferiority trial
Through the looking glass: understanding non-inferiority
Work Disability in Axial Spondyloarthritis
Handling an uncertain control group event risk in non-inferiority trials: non-inferiority frontiers and the power-stabilising transformation
Non-efficacy benefits and non-inferiority margins: a scoping review of contemporary high-impact non-inferiority trials in clinical cardiology
P190: Cardiovascular Disease in Axial Spondyloarthritis
Targeting inflammatory pathways in axial spondyloarthritis
Novel Therapeutic Targets in Axial Spondyloarthritis
Bayes factors for superiority, non-inferiority, and equivalence designs
Understanding the null hypothesis (H0) in non-inferiority trials
Demonstrating equivalence and non-inferiority of medical education concepts
Nonradiographic axial spondyloarthritis: clinical and therapeutic relevance
Dose reduction and withdrawal strategy for TNF-inhibitors in psoriatic arthritis and axial spondyloarthritis: design of a pragmatic open-label, randomised, non-inferiority trial
Through the looking glass: understanding non-inferiority
Work Disability in Axial Spondyloarthritis
Handling an uncertain control group event risk in non-inferiority trials: non-inferiority frontiers and the power-stabilising transformation
Non-efficacy benefits and non-inferiority margins: a scoping review of contemporary high-impact non-inferiority trials in clinical cardiology
P190: Cardiovascular Disease in Axial Spondyloarthritis
Targeting inflammatory pathways in axial spondyloarthritis
Novel Therapeutic Targets in Axial Spondyloarthritis
Bayes factors for superiority, non-inferiority, and equivalence designs
Understanding the null hypothesis (H0) in non-inferiority trials
Demonstrating equivalence and non-inferiority of medical education concepts